Curonix Freedom PNS System Demonstrates 69% Response Rate in First FDA-Approved Randomized Trial for Chronic Craniofacial Pain
核心洞察
Curonix's Freedom Peripheral Nerve Stimulator System (搜索) achieved a 69% response rate with ≥50% pain reduction at three months compared to only 11% in the control group (p<0.001).
The active stimulation group reported a 62% mean reduction in Visual Analog Scale pain scores versus 8.5% in the deactivated control group at three months.
The landmark prospective, multi-center, randomized FDA-approved IDE clinical trial provides Level I evidence and resulted in an FDA 510(k) expanded indication.
Curonix LLC has published results from the first and only FDA-approved IDE randomized clinical trial evaluating peripheral nerve (搜索) stimulation for chronic craniofacial pain (搜索), demonstrating significant efficacy with 69% of patients achieving clinically meaningful pain reduction. The study, published in Pain Physician by Hayek et al., provides Level I evidence supporting the Freedom Peripheral Nerve Stimulator System (搜索) and has led to an FDA 510(k) expanded indication for treating chronic craniofacial pain.
Clinical Trial Results Show Strong Efficacy
The prospective, multi-center, randomized controlled trial revealed compelling efficacy data for the Freedom PNS System. At three months, 69% of patients receiving active stimulation achieved a ≥50% pain reduction compared to only 11% of the deactivated control group (p<0.001). The active stimulation group demonstrated a 62% mean reduction in Visual Analog Scale (VAS) pain scores, while the deactivated control group reported only an 8.5% reduction (p<0.001) at three months.
Importantly, the mean pain reduction and improved function were sustained through 12 months of follow-up, indicating durable therapeutic benefit. The study also documented significant improvements in quality of life measures using the SF-36 scale, patient global impression of change (PGIC), and reductions in daily pain interference as measured by the Brief Pain Inventory-Facial (BPIF).
Safety Profile and Technology Overview
The trial reported no serious adverse events (SAEs), supporting the safety profile of the Freedom PNS System. The device represents what Curonix describes as "the only full-body permanent PNS system" designed to safely deliver significant and long-term pain reduction.
The Freedom PNS System utilizes a unique non-integrated, minimally-invasive design that does not include an implanted battery. Instead, the system is powered by High-Frequency Electromagnetic Coupling (HF-EMC) and comprises a two-component implantable neurostimulator, an externally worn transmitter, and software for patient-specific stimulation programming. The neurostimulator consists of an electrode array and a separate surgically connected receiver, anchored within two separate incisions including the creation of a subcutaneous pocket.
Clinical Impact and Future Directions
"This publication represents a significant milestone for thousands of patients suffering from chronic pain (搜索), the Freedom PNS System, and the PNS therapy overall," said Aure Bruneau, CEO of Curonix. "The Freedom PNS system delivers a safe, long-lasting relief alternative to treat chronic craniofacial pain (搜索)."
The study contributes to an expanding body of PNS evidence that now includes over 350 study patients implanted with PNS devices across peer-reviewed publications. Curonix has indicated its commitment to utilizing this foundational evidence to facilitate advanced education for healthcare providers and work with private insurers to ensure appropriate chronic pain (搜索) patients gain access to PNS therapy as a long-term permanent alternative to opioids.
The successful completion of this landmark trial and subsequent FDA 510(k) expanded indication represents a significant advancement in non-opioid neuromodulation therapies for chronic craniofacial pain (搜索) management, providing clinicians with a new evidence-based treatment option for this challenging patient population.